Bionano Genomics, Inc.
BNGO Nasdaq· Laboratory Analytical Instruments
Last close · Oct 26, 2026
$1.16
KIRA · Stoqly’s AI analyst, in plain words
- Bionano Genomics, Inc. had $28.5M of revenue in fiscal 2025, down 7.4% on the year before. Over five years, revenue changed +27.4% a year on average.
- Its operating margin was −116.9%, up 220.9 pts: of every 100 in sales, about −117 is left after running the business.
- Bionano Genomics, Inc. lost $26.4M in fiscal 2025.
Market cap
$13.4M
P/E
—
Revenue
$28.5M
Net income
−$26.4M
Free cash flow
—
Operating margin
−116.9%
Bionano Genomics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−7.4%
No. Sales fell 7.4% last year.
Does it make a profit?
−92.6%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Bionano Genomics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Bionano Genomics, Inc.
- CIK
- 0001411690
Bionano Genomics, Inc. · BNGO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Revenue growth | 111.5% | 54.6% | 29.9% | −14.8% | −7.4% |
| Gross margin | 21.5% | 21.4% | 26.5% | 1.2% | 46.3% |
| Operating margin | −428.8% | −473.7% | −596.0% | −337.9% | −116.9% |
| Net income | −$72.4M | −$133M | −$232M | −$112M | −$26.4M |
| Net margin | −402.8% | −476.9% | −643.7% | −364.0% | −92.6% |
| Diluted EPS | −$0.26 | −$4.58 | −$408.60 | −$88.13 | −$4.85 |
| Cash | |||||
| Cash from operations | −$71.9M | −$125M | −$125M | −$68.9M | −$16.3M |
| Share count change | 165.5% | −89.6% | −98.0% | 123.4% | 328.4% |
| Debt and strength | |||||
| Cash and short-term investments | $251M | $113M | $66.8M | $9.5M | $19.3M |
| Debt incl. finance leases | $3.9M | — | — | — | — |
| Shareholders' equity | $337M | $249M | $96.2M | $35.4M | $44.4M |
| Current ratio | 12.5x | 4.4x | 1.4x | 1.1x | 2.0x |
| Interest coverage | −83.2x | −441.9x | −42.0x | — | — |
| Returns and quality | |||||
| Return on capital | −70.4% | — | — | — | — |
| Return on equity | −38.9% | −45.2% | −134.6% | −170.3% | −66.2% |
| Return on tangible equity | −28.5% | −101.2% | −373.9% | −436.4% | −65.9% |
| Piotroski F-score | 4 | 3 | 4 | 2 | 4 |
| Altman Z'' | 10.0 | 0.5 | −13.5 | −37.5 | −31.3 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bionano Genomics, Inc. · BNGO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.16 a share, the company is worth $13.4M.
Source: SEC EDGAR XBRL filings (CIK 0001411690). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.